Cardiol Therapeutics Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- David G. Elsley
- Full Time Employees
- 18
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 2265 Upper Middle Road East Oakville ON Canada L6H 0G5
- IPO Date
- Jan 15, 2019
- CIK
- 0001702123
- Website
- cardiolrx.com
- Similar Companies
- Business
- Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's core products include CardiolRx, an oral pharmaceutically manufactured cannabidiol formulation, targeting rare cardiac conditions such as recurrent pericarditis and acute myocarditis, and CRD-38, a novel subcutaneously administered cannabidiol formulation for inflammatory heart diseases including heart failure. CardiolRx aims to modulate inflammasome pathway activation to reduce inflammation and fibrosis in the heart, representing a potential disease-modifying, non-immunosuppressive treatment option. Recent major developments include positive Phase II ARCHER trial results demonstrating significant improvements in cardiac structure and function in patients with acute myocarditis, ahead-of-schedule patient enrollment completion for this trial, advancement of the Phase III MAVERIC trial in recurrent pericarditis, and a Notice of Allowance from the US Patent and Trademark Office covering cannabidiol compositions for cardiac treatments protecting CardiolRx and CRD-38 through 2040. The company raised $11 million via a private placement in 2025 to support its clinical pipeline and received a Buy rating with a price target of $6.00 by Brookline Capital Markets. Cardiol Therapeutics operates primarily in Canada and the United States and is headquartered in Toronto, Canada. Founded in 2014, it collaborates with international research institutions including Tecnológico de Monterrey and the DeBakey Heart and Vascular Center in Houston for development of its therapies targeting inflammation and fibrosis in cardiovascular diseases.
Company News
Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy
Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission
Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference
Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?
Cardiol Therapeutics Inc. (CRDL) is a Great Momentum Stock: Should You Buy?
Cardiol Therapeutics Advances CardiolRx in Pivotal Phase III Pericarditis Trial
Cardiol Therapeutics (CRDL) Expected to Post Earnings on Thursday
Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference
Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association
Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit
Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders
Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT
Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ
Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association
Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program
Contrasting Corcept Therapeutics (NASDAQ:CORT) & Cardiol Therapeutics (NASDAQ:CRDL)
Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart
Cardiol Therapeutics Announces Year-End 2025 Update on Operations